Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) on January 27 and set a price target of $38.00. The company’s shares closed last Friday at $40.68.
According to TipRanks, Samimy is a 4-star analyst with an average return of 9.0% and a 51.34% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Supernus Pharmaceuticals with a $43.33 average price target.
See the top stocks recommended by analysts >>
Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $177.35 million and a net profit of $1.75 million. In comparison, last year the company earned a revenue of $148.46 million and had a net profit of $21.56 million
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SUPN in relation to earlier this year. Earlier this month, Frederick Hudson, a Director at SUPN bought 8,722.00 shares for a total of $68,903.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Read More on SUPN:
